Refine
Year of publication
Document Type
- Article (21)
- Preprint (2)
- Working Paper (2)
Language
- English (25)
Has Fulltext
- yes (25)
Is part of the Bibliography
- no (25)
Keywords
- LHC (4)
- ALICE (2)
- (sub-) luxation (1)
- 900 GeV (1)
- ALICE experiment (1)
- Active middle ear implants (1)
- Auditory system (1)
- B cell receptor (1)
- Bone conduction devices (1)
- Colorectal cancer (1)
- Comparison with QCD (1)
- Consensus statement (1)
- DSGE (1)
- Developmental biology (1)
- Diagnostic markers (1)
- Drug screens (1)
- Electron-pion identification (1)
- Evidence-based guidelines (1)
- Experimental models of disease (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- HBT (1)
- Hadron production (1)
- Health policy (1)
- Heavy flavour production (1)
- Heavy-ion collisions (1)
- Hematology (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- Ionisation energy loss (1)
- JAWSTAT pathway (1)
- Leukemias (1)
- Mixed hearing loss (1)
- Multi-stakeholder approach (1)
- Multi-wire proportional drift chamber (1)
- Nephrons (1)
- Neural network (1)
- Nuclear modification factor (1)
- Numerical accuracy (1)
- Oncology (1)
- PYTHIA (1)
- Pb–Pb (1)
- Psoriasis vulgaris (1)
- Rehabilitation (1)
- Respiratory signs and symptoms (1)
- STAT3 (1)
- Single muons (1)
- Solution methods (1)
- Surgery (1)
- TR (1)
- Technical data (1)
- Tracking (1)
- Transition radiation detector (1)
- Translational research (1)
- Transverse momentum (1)
- Trauma (1)
- Treatment (1)
- Trigger (1)
- Xenon-based gas mixture (1)
- cell proliferation (1)
- cost-effective (1)
- dE/dx (1)
- dislocation (1)
- ectosomes (1)
- exosomes (1)
- extracellular vesicles (1)
- guidelines (1)
- intraoperatively molded (1)
- inverse spacer (1)
- microparticles (1)
- microvesicles (1)
- minimal information requirements (1)
- pp collisions (1)
- reproducibility (1)
- revision knee arthroplasty (1)
- rigor (1)
- standardization (1)
- xenograft (1)
- √sN N = 2.76 TeV (1)
Institute
Colorectal carcinoma (CRC) is a major cause of morbidity and mortality in Western countries. It has so far been molecularly defined mainly by alterations of the Wnt pathway. We show here for the first time that aberrant activities of the signal transducer and activator of transcription STAT3 actively contribute to this malignancy and, thus, are a potential therapeutic target for CRC. Constitutive STAT3 activity was found to be abundant in dedifferentiated cancer cells and infiltrating lymphocytes of CRC samples, but not in non-neoplastic colon epithelium. Cell lines derived from malignant colorectal tumors lost persistent STAT3 activity in culture. However, implantation of colon carcinoma cells into nude mice resulted in restoration of STAT3 activity, suggesting a role of an extracellular stimulus within the tumor microenvironment as a trigger for STAT activation. STAT3 activity in CRC cells triggered through interleukin-6 or through a constitutively active STAT3 mutant promoted cancer cell multiplication, whereas STAT3 inhibition through a dominant-negative variant impaired IL-6-driven proliferation. Blockade of STAT3 activation in CRCderived xenograft tumors slowed down their development, arguing for a contribution of STAT3 to colorectal tumor growth.
Psoriasis vulgaris is a common and chronic inflammatory skin disease which has the potential to significantly reduce the quality of life in severely affected patients. The incidence of psoriasis in Western industrialized countries ranges from 1.5 to 2%. Despite the large variety of treatment options available, patient surveys have revealed insufficient satisfaction with the efficacy of available treatments and a high rate of medication non-compliance. To optimize the treatment of psoriasis in Germany, the Deutsche Dermatologische Gesellschaft and the Berufsverband Deutscher Dermatologen (BVDD) have initiated a project to develop evidence-based guidelines for the management of psoriasis. The guidelines focus on induction therapy in cases of mild, moderate, and severe plaque-type psoriasis in adults. The short version of the guidelines reported here consist of a series of therapeutic recommendations that are based on a systematic literature search and subsequent discussion with experts in the field; they have been approved by a team of dermatology experts. In addition to the therapeutic recommendations provided in this short version, the full version of the guidelines includes information on contraindications, adverse events, drug interactions, practicality, and costs as well as detailed information on how best to apply the treatments described (for full version, please see Nast et al., JDDG, Suppl 2:S1–S126, 2006; or http://www.psoriasis-leitlinie.de).
Non-standard errors
(2021)
In statistics, samples are drawn from a population in a data-generating process (DGP). Standard errors measure the uncertainty in sample estimates of population parameters. In science, evidence is generated to test hypotheses in an evidence-generating process (EGP). We claim that EGP variation across researchers adds uncertainty: non-standard errors. To study them, we let 164 teams test six hypotheses on the same sample. We find that non-standard errors are sizeable, on par with standard errors. Their size (i) co-varies only weakly with team merits, reproducibility, or peer rating, (ii) declines significantly after peer-feedback, and (iii) is underestimated by participants.
The last decade has seen a sharp increase in the number of scientific publications describing physiological and pathological functions of extracellular vesicles (EVs), a collective term covering various subtypes of cell-released, membranous structures, called exosomes, microvesicles, microparticles, ectosomes, oncosomes, apoptotic bodies, and many other names. However, specific issues arise when working with these entities, whose size and amount often make them difficult to obtain as relatively pure preparations, and to characterize properly. The International Society for Extracellular Vesicles (ISEV) proposed Minimal Information for Studies of Extracellular Vesicles (“MISEV”) guidelines for the field in 2014. We now update these “MISEV2014” guidelines based on evolution of the collective knowledge in the last four years. An important point to consider is that ascribing a specific function to EVs in general, or to subtypes of EVs, requires reporting of specific information beyond mere description of function in a crude, potentially contaminated, and heterogeneous preparation. For example, claims that exosomes are endowed with exquisite and specific activities remain difficult to support experimentally, given our still limited knowledge of their specific molecular machineries of biogenesis and release, as compared with other biophysically similar EVs. The MISEV2018 guidelines include tables and outlines of suggested protocols and steps to follow to document specific EV-associated functional activities. Finally, a checklist is provided with summaries of key points.
As new generations of targeted therapies emerge and tumor genome sequencing discovers increasingly comprehensive mutation repertoires, the functional relationships of mutations to tumor phenotypes remain largely unknown. Here, we measured ex vivo sensitivity of 246 blood cancers to 63 drugs alongside genome, transcriptome, and DNA methylome analysis to understand determinants of drug response. We assembled a primary blood cancer cell encyclopedia data set that revealed disease-specific sensitivities for each cancer. Within chronic lymphocytic leukemia (CLL), responses to 62% of drugs were associated with 2 or more mutations, and linked the B cell receptor (BCR) pathway to trisomy 12, an important driver of CLL. Based on drug responses, the disease could be organized into phenotypic subgroups characterized by exploitable dependencies on BCR, mTOR, or MEK signaling and associated with mutations, gene expression, and DNA methylation. Fourteen percent of CLLs were driven by mTOR signaling in a non–BCR-dependent manner. Multivariate modeling revealed immunoglobulin heavy chain variable gene (IGHV) mutation status and trisomy 12 as the most important modulators of response to kinase inhibitors in CLL. Ex vivo drug responses were associated with outcome. This study overcomes the perception that most mutations do not influence drug response of cancer, and points to an updated approach to understanding tumor biology, with implications for biomarker discovery and cancer care.